

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs ^{66.4 kg} 146 pounds. What size needle will you use?

1 in 23G = Deltoid Gluteal 1 1/2 in 22G no matter weight

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

Injection site reaction extrapyramidal disorder
Somnolence/sedation
dizziness
akathisia

3. What black box warning is associated with this medication?

↑ mortality in elderly pts ± dementia-related psychosis

4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?

Day 1 = 234mg Day 8 = 156mg

5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?

117mg

6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

Day 1 = (L) Deltoid Day 8 = (R) Deltoid

7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?

Day 1 = 117mg Day 8 = 117

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

78mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

to establish tolerability

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Hand hygiene.

Gloves

clean site with alcohol

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

It is a psychoactive drug with significant risks. Pt must understand benefits/risks and agree to tx